Linked Life Data

10722508

Source:http://linkedlifedata.com/resource/pubmed/id/10722508

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2000-5-1
pubmed:abstractText
Fifteen multiresistant Acinetobacter baumannii isolates from patients in intensive care units and 14 nonoutbreak strains were tested to determine in vitro activities of nontraditional antimicrobials, including cefepime, meropenem, netilmicin, azithromycin, doxycycline, rifampin, sulbactam, and trovafloxacin. The latter five drugs were further tested against four of the strains for bactericidal or bacteriostatic activity by performing kill-curve studies at 0.5, 1, 2, and 4 times their MICs. In addition, novel combinations of drugs with sulbactam were examined for synergistic interactions by using a checkerboard configuration. MICs at which 90% of the isolates tested were inhibited for antimicrobials showing activity against the multiresistant A. baumannii strains were as follows (in parentheses): doxycycline (1 microg/ml), azithromycin (4 microg/ml), netilmicin (1 microg/ml), rifampin (8 microg/ml), polymyxin (0.8 U/ml), meropenem (4 microg/ml), trovafloxacin (4 microg/ml), and sulbactam (8 microg/ml). In the kill-curve studies, azithromycin and rifampin were rapidly bactericidal while sulbactam was more slowly bactericidal. Trovafloxacin and doxycycline were bacteriostatic. None of the antimicrobials tested were bactericidal against all strains tested. The synergy studies demonstrated that the combinations of sulbactam with azithromycin, rifampin, doxycycline, or trovafloxacin were generally additive or indifferent.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/10722508-1656736, http://linkedlifedata.com/resource/pubmed/commentcorrection/10722508-1656743, http://linkedlifedata.com/resource/pubmed/commentcorrection/10722508-2817859, http://linkedlifedata.com/resource/pubmed/commentcorrection/10722508-7650188, http://linkedlifedata.com/resource/pubmed/commentcorrection/10722508-7795075, http://linkedlifedata.com/resource/pubmed/commentcorrection/10722508-7840598, http://linkedlifedata.com/resource/pubmed/commentcorrection/10722508-7968028, http://linkedlifedata.com/resource/pubmed/commentcorrection/10722508-8591936, http://linkedlifedata.com/resource/pubmed/commentcorrection/10722508-8783704, http://linkedlifedata.com/resource/pubmed/commentcorrection/10722508-8842272, http://linkedlifedata.com/resource/pubmed/commentcorrection/10722508-8964033
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
44
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1035-40
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak.
pubmed:affiliation
Departments of Pathology, Los Angeles County-University of Southern California Medical Center, Los Angeles, CA 90033, USA. mapplema@hsc.usc.edu
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't